MarginsXMarginsX
Home › Markets › Health Care › UNCY

Unicycive Therapeutics Inc. (UNCY)

UNCY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.70
+4.23% on the day
Market cap
$103.1M
Micro cap
Revenue · 2023
$675K
-29.0% on 2022
Net income · 2023
-$30.5M
-4525.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/0001213900-25-025828-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerUNCY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001766140
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$675K
Net income-$30.5M
Operating income-$20.8M
Net margin-4525.0%
Operating margin-3077.6%
Revenue growth-29.0%
Cash$9.7M
Total assets$14.2M
P/E (computed)Net income was not positive
P/S (computed)152.7×

Warning signs

Cash runway
19.0 months
$44.2M cash at June 30, 2026
Share count, 1 year
+57.7%
2025-08-14 to 2026-08-12 · +701.5% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-12
Cash and burn$44.2M cash; operating cash flow -$7.0M a quarter.Report 2026-06-30
Shares outstanding27,855,257 (2026-08-12); 17,661,698 a year earlier; 34,752,221 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-08-12
Reverse splits, 3 years1; latest 1-for-10 on 2025-06-20Source 2025-06-20
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrassi & Co., CPAs, P.C., Jericho, New York, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.7M-$7.6M$44.2MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$12.8M-$6.2M$37.4MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2025
2025-12-31
Not filed-$14.7M-$8.0M$29.2MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$6.0M-$6.0M$42.7MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$6.4M-$8.4M$22.3MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed$570K-$8.9M$19.8MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2024
2024-12-31
Not filed-$21.5M-$6.5M$26.1MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$4.1M-$9.3M$32.3MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-32026-06-05
Latest annual report
ANNUAL REPORT
10-K2026-03-30
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-11-16
Latest proxy
CURRENT REPORT
DEFA14A2026-06-22

Source: SEC EDGAR submissions feed, 311 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week0.0%
1 month-4.8%
3 months-34.3%
Year to date-38.5%
1 year-33.4%
From 52-week high-58.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CUECue Biopharma Inc.$14.10-12.53%$102.4M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
DERMJourney Medical Corporation$3.70-14.55%$104.5M
CLLSCellectis S.A.$1.04-11.86%$104.5M
ADAGAdagene Inc.$1.60-6.43%$105.7M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier